Clinical Trials Logo

Neoplasm, Unknown Primary clinical trials

View clinical trials related to Neoplasm, Unknown Primary.

Filter by:
  • None
  • Page 1

NCT ID: NCT00360360 Completed - Clinical trials for Neoplasm, Unknown Primary

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Start date: July 2006
Phase: Phase 2
Study type: Interventional

We will evaluate the feasibility, toxicity, and effectiveness of combination chemotherapy (paclitaxel/carboplatin)plus combination targeted therapy (bevacizumab/erlotinib)in the first line treatment of patients with carcinoma of unknown primary site. There is limited experience with either bevacizumab or erlotinib in the treatment of cancers of unknown site but given the heterogeneous nature of the tumor, it is likely that inhibition of angiogenesis pathways and/or the EGFR pathway are effective strategies in at least a proportion.